BCA
LFCR icon

Bray Capital Advisors’s Lifecore Biomedical LFCR Stock Holding History

Bray Capital Advisors’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-633
Closed -$7K – 295
2019
Q3 		$7K Hold
633
– – ﹤0.01% 276
2019
Q2 		$6K Hold
633
– – ﹤0.01% 295
2019
Q1 		$8K Hold
633
– – ﹤0.01% 267
2018
Q4 		$7K Hold
633
– – ﹤0.01% 269
2018
Q3 		$9K Buy
+633
New +$8.75K ﹤0.01% 265

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WC
Walthausen & Co Malta, New York $120M AUM 2.66% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Bray Capital Advisors's LFCR Position: Q4 2019 in Review

Bray Capital Advisors sold out of Lifecore Biomedical (LFCR) in Q4 2019, closing a stake of 633 shares — an estimated $7K sold.

Bray Capital Advisors first reported a position in LFCR in Q3 2018 and held it in 5 quarters. The position peaked at $9K in Q3 2018. 93 funds tracked by Wall St. Rank hold LFCR as of Q4 2019.

  • Bray Capital Advisors reported no remaining Lifecore Biomedical position as of Q4 2019 after selling out during the quarter.
  • Bray Capital Advisors sold 633 Lifecore Biomedical shares in Q4 2019, an estimated $7K.
  • Bray Capital Advisors first reported a position in Lifecore Biomedical in Q3 2018 and held it in 5 quarters.
  • Bray Capital Advisors's Lifecore Biomedical position peaked at $9K in Q3 2018.
  • 93 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2019.

Based on Bray Capital Advisors's 13F filing for Q4 2019, filed 31 Jan 2020.